Speaker Biography

Dr. Tanveer Ahmed
Biography:

Abstract:

Background and Objectives

Hepatitis C Virus (HCV) infection is an important health issue and leading cause of chronic liver disease in developing countries including Pakistan. Therefore, the current study was aimed to assess the treatment responses of available antiviral regimens.

Background and Objectives

Hepatitis C Virus (HCV) infection is an important health issue and leading cause of chronic liver disease in developing countries including Pakistan. Therefore, the current study was aimed to assess the treatment responses of available antiviral regimens.

Methods

A total of 144 chronic HCV positive patients by real time PCR were enrolled from Department of Gastroenterology, Pakistan Institute of Medical Sciences PIMS, Islamabad North Region, Pakistan. Treatment responses among chronic HCV positive patients were observed for antiviral regimens. These antiviral regimens were Sofosbuvir + Ribavirin 24weeks and Sofosbuvir + Daclatasvir 12Weeks.  Sofosbuvir 400mg,Sovaldi , Gilead Sciences, USA and Daclatasvir 60mg , MyDekla, Mylan , USA/Dacklinza, Bristo Myers Squibb, USA were prescribed to take orally once a day. In addition, Ribavirin Xolox, Ferozsons, Pakistan, 400mg or 600mg  had been advised to take orally twice daily on the basis of weight of patients. The end of treatment response ETR after completion of treatment and sustained virological response SVR after 12 weeks of cessation of treatment were assessed by the detection of HCV RNA in sera of treated patients.

Results

The high ETR and SVR were achieved with Sofosbuvir + Daclatasvir 12 weeks, 92.26%, 71/73 when compared with Sofosbuvir + Ribavirin 24 weeks, 84.50%, 60/71 among chronic HCV positive patients.

Conclusions

In conclusion, the 12 weeks HCV antiviral eradication regimen i.e., Sofosbuvir + Daclatasvir was more effective, economic and a better choice than 24 weeks regimen ‘Sofosbuvir + Ribavirin’ in our region.